NFE2L2 and early-onset autosomal dominant Alzheimer disease: Clinical trials with Nrf2 inducing agents such as resveratrol and curcumin in Alzheimer’s disease patients have produced limited results [86,88], presumably due to poor bioavailability and brain penetrance of the compounds [125], although a retrospective subset analysis found positive results for resveratrol on Alzheimer’s Disease Cooperative Study—Activities of Daily Living (ADCS-ADL) clinical scores [89] (Table 2).